Pre-eclampsia medical therapy: Difference between revisions

Jump to navigation Jump to search
 
Line 11: Line 11:
* The mainstay of therapy for [[hypertension]] in [[preeclampsia]] is [[oral methyldopa]], [[labetalol]], [[oxprenolol]], and [[nifedipine]], and second or third line agents include [[hydralazine]] and [[prazosin]].
* The mainstay of therapy for [[hypertension]] in [[preeclampsia]] is [[oral methyldopa]], [[labetalol]], [[oxprenolol]], and [[nifedipine]], and second or third line agents include [[hydralazine]] and [[prazosin]].
*For patients who have [[proteinuria]] with [[severe hypertension]] or [[hypertension ]] with [[neurologic]] signs and symptoms, treatment is [[magnesium sulfate]] ([[MgSO4]]) for [[convulsion]] prophylaxis.
*For patients who have [[proteinuria]] with [[severe hypertension]] or [[hypertension ]] with [[neurologic]] signs and symptoms, treatment is [[magnesium sulfate]] ([[MgSO4]]) for [[convulsion]] prophylaxis.
* Urgent therapy for [[severe hypertension]]( [[blood pressure]] >160/110) is oral [[nifedipine]] or intravenous [[labetalol]] or [[hydralazine]] or oral [[labetalol]].<ref>{{cite journal|doi=10.1161/HYP.0000000000000065Hypertension.}}</ref>
* Urgent therapy for [[severe hypertension]]( [[blood pressure]] >160/110) is oral [[nifedipine]] or intravenous [[labetalol]] or [[hydralazine]] or oral [[labetalol]].<ref>{{cite journal|doi=10.1161/HYP.0000000000000065Hypertension.}}</ref><ref name="pmid32443079">{{cite journal |vauthors= |title=Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222 |journal=Obstet Gynecol |volume=135 |issue=6 |pages=e237–e260 |date=June 2020 |pmid=32443079 |doi=10.1097/AOG.0000000000003891 |url=}}</ref>
{| class="wikitable"
{| class="wikitable"
|-
|-

Latest revision as of 06:38, 11 March 2022

Pre-eclampsia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pre-eclampsia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pre-eclampsia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pre-eclampsia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pre-eclampsia medical therapy

CDC on Pre-eclampsia medical therapy

Pre-eclampsia medical therapy in the news

Blogs on Pre-eclampsia medical therapy

Directions to Hospitals Treating Pre-eclampsia

Risk calculators and risk factors for Pre-eclampsia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Ogheneochuko Ajari, MB.BS, MS [3]

Overview


Treatment

Medical Therapy

Serum Magnesium Concentration (mg/dL) Effect
5–9 Therapeutic range
>9 Loss of patellar reflexes
> 12 Respiratory paralysis
> 30 Cardiac arrest
Drugs for urgent controlling of hypertension in preeclampsia[3] Dose Specific considration Onset of action
Labetalol 10–20 mg IV, then 20–80 mg every 10–30 minutes upto a maximum dosage of 300 mg; or infusion 1–2 mg/min IV Contraindications: 1-2 minutes
Hydralazine 5 mg IV or IM, then 5–10 mg IV every 20–40 minutes upto a maximum dosage of 20 mg or keeping infusion of 0.5–10 mg/hr Side effects in higher dosage: 10-20 minutes
Nifedipine 10–20 mg orally, repeat in 20 minutes if needed; then 10–20 mg every 2–6 hours, maximum daily dose is 180 mg Side effect: 5-10 minutes

References

  1. . doi:10.1161/HYP.0000000000000065Hypertension. Check |doi= value (help). Missing or empty |title= (help)
  2. "Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222". Obstet Gynecol. 135 (6): e237–e260. June 2020. doi:10.1097/AOG.0000000000003891. PMID 32443079 Check |pmid= value (help).
  3. "Gestational Hypertension and Preeclampsia". Obstetrics & Gynecology. 135 (6): e237–e260. 2020. doi:10.1097/AOG.0000000000003891. ISSN 0029-7844.